NCT00129571已完成1 期
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of XL820 Administered Orally to Subjects With Solid Tumors
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Exelixis
- 试验地点
- 4
研究概览
简要总结
The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Advanced solid tumor
- •Cancer for which standard therapies do not exist or are no longer effective
- •Life expectancy of > 3 months
- •Adequate bone marrow, liver, and kidney function
- •Willing to use accepted method of contraception during the course of the study
- •Negative pregnancy test (females)
- •Written informed consent
排除标准
- •Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
- •Radiotherapy to more than 25% of bone marrow within 4 weeks of the start of treatment
- •Investigational drug within 30 days of the start of treatment
- •Subjects with known brain metastasis
- •Uncontrolled medical disorder such as infection or cardiovascular disease
- •Subjects known to be HIV positive
- •Pregnant or breastfeeding women
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Study of XL184 (Cabozantinib) in Adults With Advanced MalignanciesCancerLymphomaThyroid CarcinomaNCT00215605Exelixis85
终止
1 期
Safety Study of Pharmacokinetics of XL888 in Adults With Solid TumorsCancerNCT00796484Exelixis33
终止
1 期
Safety Study of XL844 in Subjects With Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT00234481Exelixis
已完成
1 期
Study of XL820 Given Orally Daily to Subjects With Solid TumorsCancerNCT00350831Exelixis30
已完成
1 期
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With GlioblastomaGiant Cell GlioblastomaGliosarcomaGlioblastomaNCT00960492Exelixis26